Susquehanna International Group LLP Has $1.68 Million Position in Electromed, Inc. (NYSE:ELMD)

Susquehanna International Group LLP lifted its stake in Electromed, Inc. (NYSE:ELMD - Free Report) by 121.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,726 shares of the company's stock after purchasing an additional 31,148 shares during the period. Susquehanna International Group LLP owned approximately 0.66% of Electromed worth $1,676,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in ELMD. Tower Research Capital LLC TRC grew its stake in Electromed by 426.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,055 shares of the company's stock valued at $149,000 after acquiring an additional 4,095 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in shares of Electromed by 30.8% in the fourth quarter. NewEdge Advisors LLC now owns 14,951 shares of the company's stock valued at $442,000 after purchasing an additional 3,517 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of Electromed in the fourth quarter valued at approximately $237,000. XTX Topco Ltd purchased a new position in shares of Electromed during the 4th quarter worth approximately $308,000. Finally, Barclays PLC increased its stake in shares of Electromed by 25.0% during the 4th quarter. Barclays PLC now owns 12,529 shares of the company's stock worth $371,000 after purchasing an additional 2,507 shares in the last quarter. Hedge funds and other institutional investors own 40.82% of the company's stock.

Electromed Stock Performance

ELMD traded up $1.44 on Friday, reaching $20.99. 97,653 shares of the company's stock were exchanged, compared to its average volume of 88,080. Electromed, Inc. has a twelve month low of $13.74 and a twelve month high of $35.56. The company's 50 day moving average is $23.17 and its 200-day moving average is $27.27. The company has a market cap of $179.62 million, a price-to-earnings ratio of 27.99 and a beta of 0.46.

Electromed declared that its board has authorized a share buyback plan on Monday, March 10th that authorizes the company to repurchase $5.00 million in shares. This repurchase authorization authorizes the company to buy up to 2.4% of its stock through open market purchases. Stock repurchase plans are often a sign that the company's leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research firms recently commented on ELMD. StockNews.com lowered Electromed from a "strong-buy" rating to a "buy" rating in a research note on Thursday, May 8th. B. Riley initiated coverage on shares of Electromed in a report on Thursday, February 20th. They set a "buy" rating and a $38.00 price target for the company.

Insider Activity

In other Electromed news, Director Andrew Summers sold 50,751 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.30, for a total transaction of $1,385,502.30. Following the transaction, the director now owns 65,714 shares of the company's stock, valued at $1,793,992.20. This trade represents a 43.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Kathleen Skarvan sold 38,954 shares of the business's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $29.28, for a total transaction of $1,140,573.12. Following the sale, the director now directly owns 32,622 shares of the company's stock, valued at approximately $955,172.16. This represents a 54.42% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 124,978 shares of company stock worth $3,542,996. 14.00% of the stock is currently owned by corporate insiders.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.